Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original): A method for treating Alzheimer's disease, the method comprising administering to a patient suffering from Alzheimer's disease a therapeutic agent selected from the group consisting of D-cycloserine and a salt of D-cycloserine, wherein the amount of the therapeutic agent is equivalent to 105-500 mg of D-cycloserine per day, and wherein the therapeutic agent is administered to the patient for at least four weeks.

2. (Original): The method of claim 1, wherein the therapeutic agent is selected from the group consisting of a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a zinc salt, and an ammonium salt of D-cycloserine.

3. (Original): The method of claim 1, wherein the D-cycloserine or salt of D-cycloserine is administered in a dose equivalent to 125-400 mg of D-cycloserine per day.

4. (Original): The method of claim 1, wherein the D-cycloserine or salt of D-cycloserine is administered in a dose equivalent to 150-300 mg of D-cycloserine per day.

5. (Original): The method of claim 1, wherein the composition is administered orally, intravenously, trans-mucosally, transdermally, ocularly, buccally, sublingually, intraperitoneally, intrathecally, intramuscularly, by a pulmonary route, or by depot preparation.

6. (Original): The method of claim 1, wherein the therapeutic agent is D-cycloserine and is administered for at least 6 weeks.

7. (Original): The method of claim 1, wherein the therapeutic agent is D-cycloserine and is administered for at least 8 weeks.

8. (Original): The method of claim 1, wherein the therapeutic agent is D-cycloserine and is administered for at least 4 months.

9. (Original): The method of claim 1, wherein the therapeutic agent is D-cycloserine and is administered for at least 8 months.

10. (Original): The method of claim 1, wherein the therapeutic agent is D-cycloserine and is administered for at least 12 months.

11. (Original): A method for treating Alzheimer's disease, the method comprising administering to a patient suffering from Alzheimer's disease a therapeutic agent selected from the group consisting of an ester of D-cycloserine, a precursor of D-cycloserine, and alkylated D-cycloserine, wherein the amount of the therapeutic agent is equivalent to 105-500 mg of D-cycloserine per day, and wherein the therapeutic agent is administered to the patient for at least four weeks.

12. (Original): The method of claim 11, wherein the therapeutic agent is an ester of D-cycloserine.

13. (Original): The method of claim 11, wherein the therapeutic agent is a precursor of D-cycloserine.

14. (Original): The method of claim 11, wherein the therapeutic agent is an alkylated D-cycloserine.

15. (Original): The method of claim 11, wherein the composition is administered orally, intravenously, trans-mucosally, transdermally, ocularly, buccally, sublingually, intraperitoneally, intrathecally, intramuscularly, by a pulmonary route, or by depot preparation.

16. (Original): The method of claim 11, wherein the therapeutic agent is administered for at least 6 weeks.

17. (Original): The method of claim 11, wherein the therapeutic agent is administered for at least 8 weeks.

18. (Original): The method of claim 11, wherein the therapeutic agent is administered for at least 4 months.

19. (Original): The method of claim 11, wherein the therapeutic agent is administered for at least 8 months.

20. (Original): The method of claim 11, wherein the therapeutic agent is administered for at least 12 months.

21. (Original): A method for treating Alzheimer's disease, the method comprising administering to a patient suffering from Alzheimer's disease

(i) a therapeutically effective amount of a therapeutic agent selected from the group consisting of D-cycloserine and a salt of D-cycloserine; and

(ii) an acetylcholine esterase inhibitor.

22. (Original): The method of claim 21, wherein the therapeutic agent is D-cycloserine.

23. (Original): The method of claim 21, wherein the therapeutic agent is selected from the group consisting of a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a zinc salt, and an ammonium salt of D-cycloserine.

24. (Original): The method of claim 21, wherein the acetylcholine esterase inhibitor is Donepezil or Tacrine.

25. (Currently amended): The method of claim 21, wherein the amount of the therapeutic agent is equivalent to 105-500 mg of D-cycloserine.

26. (Original): The method of claim 25, wherein the amount of the therapeutic agent is equivalent to 125-400 mg of D-cycloserine per day.

27. (Original): The method of claim 26, wherein the amount of the therapeutic agent is equivalent to 150-300 mg of D-cycloserine per day.

28. (Original): The method of claim 21, wherein the therapeutic agent and the acetylcholine esterase inhibitor are administered orally, intravenously, trans-mucosally, transdermally, ocularly, buccally, sublingually, intraperitoneally, intrathecally, intramuscularly, by a pulmonary route, or by depot preparation.

29. (Original): A method for treating Alzheimer's disease, the method comprising administering to a patient suffering from Alzheimer's disease

(i) a therapeutically effective amount of a therapeutic agent selected from the group consisting of an ester of D-cycloserine, a precursor of D-cycloserine, and alkylated D-cycloserine; and

(ii) an acetylcholine esterase inhibitor.

30. (Original): The method of claim 29, wherein the therapeutic agent is an ester of D-cycloserine having an ester group with 1-20 carbon atoms.

31. (Original): The method of claim 29, wherein the therapeutic agent is an alkylated D-cycloserine having an alkyl group with 1-20 carbon atoms.

32. (Original): The method of claim 29, wherein the therapeutic agent is a precursor of D-cycloserine.

33. (Original): The method of claim 29, wherein the acetylcholine esterase inhibitor is Donepezil or Tacrine.

34. (Original): The method of claim 29, wherein the amount of the therapeutic agent is equivalent to 105-500 mg of D-cycloserine.

35. (Original): The method of claim 34, wherein the amount of the therapeutic agent is equivalent to 125-400 mg of D-cycloserine per day.

36. (Original): The method of claim 35, wherein the amount of the therapeutic agent is equivalent to 150-300 mg of D-cycloserine per day.

37. (Currently amended): The method of claim 29, wherein the therapeutic ~~agents~~ agent and the acetylcholine esterase inhibitor are administered orally, intravenously, trans-mucosally, transdermally, ocularly, buccally, sublingually, intraperitoneally, intrathecally, intramuscularly, by a pulmonary route, or by depot preparation.

38. (Original): A method for treating Alzheimer's disease, the method comprising administering to a patient diagnosed as suffering from Alzheimer's disease

(i) a first therapeutic agent selected from the group consisting of D-cycloserine and a salt of D-cycloserine; and

(ii) a second therapeutic agent selected from the group consisting of antipsychotics, antidepressants, psychostimulants, and Alzheimer's disease therapeutics;

wherein the therapeutic agent is equivalent to 105-500 mg of D-cycloserine.

39. (Original): A method for treating Alzheimer's disease, the method comprising administering to a patient diagnosed as suffering from Alzheimer's disease

(i) a first therapeutic agent selected from the group consisting of an ester of D-cycloserine, a precursor of D-cycloserine, and alkylated D-cycloserine; and

(ii) a second therapeutic agent selected from the group consisting of antipsychotics, antidepressants, psychostimulants, and Alzheimer's disease therapeutics;

wherein the first therapeutic agent is in an amount equivalent to 105-500 mg of D-cycloserine.

40. (Original): A pharmaceutical composition comprising:

(i) a therapeutically effective amount of a therapeutic agent selected from the group consisting of D-cycloserine and a salt of D-cycloserine; and

(ii) an acetylcholine esterase inhibitor.

41. (Currently amended): The ~~method~~ composition of claim 40, wherein the therapeutic agent is equivalent to 105-500 mg of D-cycloserine.

42. (Original): The composition of claim 40, wherein the therapeutic agent is selected from the group consisting of a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a zinc salt, and an ammonium salt of D-cycloserine.

43. (Original): The composition of claim 40, wherein acetylcholine esterase inhibitor is Donepezil or Tacrine.

44. (Original): A pharmaceutical composition comprising:

(i) a therapeutically effective amount of a therapeutic agent selected from the group consisting of an ester of D-cycloserine, a precursor of D-cycloserine, and alkylated D-cycloserine; and

(ii) an acetylcholine esterase inhibitor.

45. (Currently amended): The ~~method~~ composition of claim 44, wherein the amount of the therapeutic agent is equivalent to 105-500 mg of D-cycloserine.

46. (Original): The composition of claim 44, wherein the acetylcholine esterase inhibitor is Donepezil or Tacrine.

47. (Original): A pharmaceutical composition comprising:

(i) a first therapeutic agent selected from the group consisting of D-cycloserine and a salt of D-cycloserine; and

(ii) a second therapeutic agent selected from the group consisting of antipsychotics, antidepressants, psychostimulants, and Alzheimer's disease therapeutics;

wherein the therapeutic agent is in an amount equivalent to 105-500 mg of D-cycloserine.

48. (Original): A pharmaceutical composition comprising:

(i) a first therapeutic agent selected from the group consisting of an ester of D-cycloserine, a precursor of D-cycloserine, and alkylated D-cycloserine; and

(ii) a second therapeutic agent selected from the group consisting of antipsychotics, antidepressants, psychostimulants, and Alzheimer's disease therapeutics;

wherein the therapeutic agent is in an amount equivalent to 105-500 mg of D-cycloserine.